MedTrace Logo

Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG

NCT04735536 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-11-29

Study results available
· View outcomes & findings →

Summary

This is a single-site, randomized, double-blind, placebo-controlled, 29-day, 2-period crossover Phase 2 study of 1 dose level of CT1812 (active) or placebo in adults with mild to moderate AD.

Conditions

  • Alzheimer Disease

Interventions

DRUG

CT1812

Active Treatment- CT1812 at a dose of 300mg

OTHER

Placebo

Placebo Comparator

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Cognition Therapeutics

    lead INDUSTRY

Principal Investigators

  • Everard Vijverberg, MD · Brain Research Center, Amsterdam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-09
Primary Completion
2023-04-26
Completion
2023-04-26
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04735536 on ClinicalTrials.gov